
Opinion|Videos|December 11, 2024
Case 2: Low-Volume Recurrent mCSPC
Key Takeaways
Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
3
Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy
4
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
5








